Registration is required to attend this symposium – Limited space available 250 seats

5th Canadian Symposium on HCV / 5ième Symposium canadien sur le VHC
Theme “We’re not Done Yet: Remaining Challenges in Hepatitis C”

February 26, 2016 / 26 février 2016
Fairmont The Queen Elizabeth Hotel, Montréal, QC
Salon St. François

Program – Programme

07h15 - 08h00  Registration, Breakfast, Exhibition and Poster Area Opens – Inscription, déjeuner et ouverture de la salle des affiches
08h00 - 08h15  Welcome and Introductions – Mot de bienvenue
Dr. Naglaa Shoukry, Université de Montréal, Montréal, Canada

Biomedical Sciences
Co-Chairs: Dr. Hugo Soudeyns and Dr. Sonya MacParland

08:15 - 08h45  Opening Keynote: How Close Are we to Realizing an HCV Vaccine?
Dr. Andrea Cox, Johns Hopkins University, Baltimore, USA

08h45 - 09h05  Is it Time to Move on from HCV? A Basic Science Perspective
Dr. Daniel Lamarre, Université de Montréal, Montréal, Canada

Oral Presentations – Présentations orales

09h05 - 09h55  Transcriptomic Characterization of the Immune Response to Acute Hepatitis C Virus Infection
Dr. Naglaa Shoukry, Université de Montréal, Montréal, Canada

09h15 - 09h25  Investigating the Mechanisms of Action of Neutralizing Antibody Responses Elicited by a Recombinant Hepatitis C Virus Envelope Glycoprotein E1E2 Vaccine
Jason A. Wong, University of Alberta, Edmonton, Canada

Clinical Sciences
Co-Chairs: Dr. Marc Bilodeau and Dr. Lisa Barrett

09h25 - 09h55  Targeting HCV: What Have we Learned from Real World Roll Out of DAAs?
Dr. David Nelson, University of Florida, Gainesville, USA

09h55 - 10h10  Coffee Break – Pause café

10h10 - 10h30  Will HCV Antiviral Resistance Matter?
Dr. Richard Harrigan, University of British Columbia, Vancouver, Canada

Oral Presentations - Présentations orales

10h30 - 10h40  Real Life Clinical Experience with Second Generation Directly Acting Antiviral (DAA) Drugs for the Treatment of Chronic Hepatitis C in Calgary, Alberta, Canada
Dr. Golasa Samadi Kochaksaraei, University of Calgary, Calgary, Canada

10h40 - 10h50  Real Life Experience of Hepatitis C Management with Interferon-Free DAA Treatments in Montreal
Dr. Emmanuelle Huchet, Clinique Médicale l’Actuel, Montréal, Canada

Epidemiology and Public Health
Co-Chairs: Dr. Julie Bruneau and Sahar Saeed

10h50 - 11h20  HCV Prevention: Modeling the Impact of Expanding HCV Treatment
Dr. Matthew Hickman, University of Bristol, Bristol, UK

11h20 - 11h40  Harm Reduction Along the HCV Prevention and Care Continuum
Dr. Joseph Cox, McGill University Health Centre, Montréal, Canada
Oral Presentations - Présentations orales

11h40 - 11h50  Correctional Facilities As HCV Treatment Access Point: a Framework for Corrections Research and HCV Treatment
Dr. Lisa Barrett, Dalhousie University, Halifax, Canada

11h50 - 12h00  Risk of Hepatitis C Virus Re-Infection or Late Relapse after Sustained Virologic Response to Interferon-based Therapy in HIV Co-infected Canadians
Carmine Rossi, McGill University, Montréal, Canada

12h00 - 13h15  Lunch – Diner: Saint-Laurent and Gatineau, Convention Floor

Behavioural Sciences
Co-Chairs: Dr. Benedikt Fischer and Emmanuel Fortier

13h15 - 13h45  Challenges in Implementing HCV Therapy Broadly in Low and Middle Income Countries
Dr. Manal El-Sayed, Ain Shams University, Cairo, Egypt

13h45 - 14h05  How Indigenous Methodologies can Inform our Response to the HCV Epidemic in Canada
Renée Masching, Canadian Aboriginal AIDS Network, Dartmouth, Canada

Oral Presentations - Présentations orales

14h05 - 14h15  Community-Directed Research Priorities for Those with Indigenous Lived Hepatitis C Experience
Dr. Manal El-Sayed, Ain Shams University, Cairo, Egypt

14h15 - 14h25  CACTUS Montreal: Initiatives to Identify Needs of PWID to Provide a Support and Increase Their Hep C Treatment Access
Julie Bouchard, CACTUS Montréal, Montréal, Canada

14h25 - 14h40  Coffee Break – Pause café

14h40 - 14h50  The Evolving Role of Nurses in the Hepatitis C Care
Geri Hirsch, Nova Scotia Health Authority, Halifax, Canada

14h50 - 15h00  Patient Advocate

15h00 - 15h40  Debate: ‘Is an HCV Vaccine Really Needed?’
Pro: Dr. Andrea Cox, Johns Hopkins University, Baltimore, USA
Con: Dr. David Wong, University Health Network, Toronto, Canada
Moderator: Dr. Jason Grebely, University of New South Wales, Sydney, Australia

15h40 - 15h50  Update on Restriction of Reimbursement of Treatments/Drugs in Canada
Alison Marshall, University of New South Wales, Sydney, Australia

15h50 - 16h30  Panel and Audience Discussion – Table ronde et discussion avec l’audience
From Research to Action: How to Translate Research into Policy Change
Moderator: Dr. Mel Krajden, University of British Columbia, Vancouver, Canada
Panelists: Glenn Betteridge, CTAC, Dr. Howard Njoo, PHAC, Dr. Dan Werb, University of San Diego

16h30 - 16h45  Closing Remarks – Mot de la fin
Dr. Marina Klein, McGill University, Montréal, Canada

16h45 - 18h30  Cocktail and Poster Session – Cocktail et présentation des affiches: Saint-Laurent and Gatineau, Convention Floor

Organizing Committee - Comité organisateur
Marina Klein, McGill University, Chair
Selena M. Sagan, McGill University, Co-Chair
Julie Bruneau, Université de Montréal
Frank Bialystok, University of Toronto
Curtis Cooper, University of Ottawa
Maryam Ehteshami, Emory University
Jordan Feld, University Health Network
Jason Grebely, University of New South Wales
Matthias Götte, University of Alberta
Mel Krajden, University of British Columbia
Gerry Mugford, Memorial University
Rodney Russell, Memorial University
Sahar Saeed, McGill University (Trainee Representative)
Luis Schang, University of Alberta
Naglaa Shoukry, Université de Montréal
Nicholas van Buuren, Stanford University
Joyce Wilson, University of Saskatchewan

For more information please contact Norma Choucha at ncrtp.hepc@gmail.com
Pour plus d’information, veuillez communiquer avec Norma Choucha @ ncrtp.hepc@gmail.com